Cancer Chemotherapy

Dr. Sachin Almel has been associated with Department of Medical Oncology, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai since July 1995.

Educational Qualification:

1988 - M.B.B.S., South Gujarat University

1992 - M.D. (Internal Medicine), South Gujarat University

1995 - D.M. (Onco Medicine) , Gujarat University

Experience:

He has also been involved in various clinical trials conducted at the Institute, the most notable being the MCP-841 and MCP-842 trials in collaboration with National Cancer Institute, U.S.A. for Acute Leukemia and High Grade Non-Hodgkin's lymphomas. During his basic training in department of Internal Medicine, he has worked in-

• Department of Cardiology for 3 months
• Department of Pulmonary Diseases for 3 months
• Department of Nephrology for 3 months

He has also worked for 3 months in the casualty department and has an adequate knowledge of handling emergency cases.

Clinical Trials Experience:

No. of years of experience in clinical trials: 5 Years

• Project Title: A Randomized, Double-Blind, and Multicentere Study of xxx Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in subjects with Prostrate Cancer 

              PI: DR ASHA KAPADIA

             CO-PI: DR SACHIN V ALMEL

• Project Title: A Randomized phase 2 Trial of Double-Blind, Placebo Controlled xxx in Combination with Paclitaxel, as First Line Therapy in Women with HER2Negative Locally Recurrent or Metastatic Breast Cancer

              PI: DR SACHIN ALMEL

             CO-PI:DR ASHA KAPADIA

• Project Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Study of Post - Operative Adjuvant XXX or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance XXX or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of Head and Neck (SCCHN).”

              PI: DR SACHIN ALMEL

             CO-PI: DR ASHA KAPADIA

• Project Title: A multicentere, open-label, phase II study of XXX XXX for efficacy and Safety in patients with Metastatic breast cancer

              PI: DR SACHIN ALMEL

             CO-PI: DR ASHA KAPADIA

• Project Title: A Randomized, Open-Label, Multicenter, Phase 3 Study of xxx Plus Standard Supportive Care versus Standard Supportive Care in   Anemic Patients with Metastatic Breast Cancer Receiving Standard Chemotherapy

              PI: DR SACHIN ALMEL

             CO-PI: DR ASHA KAPADIA

• Project Title: A Phase 1b / 2 Trial of XXX or XXX in Combination with Platinum-based    Chemotherapy      as First-Line Treatment for Extensive Stage Small Cell Lung Cancer”

             PI: DR SACHIN ALMEL

            CO-PI: DR ASHA KAPADIA

• Project Title: A Phase 3, Randomized, Double-Blinded Study of xxxxxxxxxx and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

             PI: DR SACHIN ALMEL

            CO-PI: DR ASHA KAPADIA

• Project Title: A Phase 3, randomized, double-blind, placebo-controlled study of oral xxx in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens

              PI: DR SACHIN ALMEL

             CO-PI: DR ASHA KAPADIA

• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of xxxxxxxx as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE).

             PI: DR SACHIN ALMEL

            CO-PI: DR ASHA KAPADIA

ICH-GCP Training:

Has Received ICH-GCP Training at PI meet held at Bangkok on 26th and 27th July 2008

• Clinical profile of cerebral Malaria: A study of 35 cases.  Thesis presented for the Degree of M.D. in Internal Medicine, South Gujarat University, Surat
• Patterns of relapse in acute leukemia: A study of 25 cases.  Thesis presented to Gujarat University, Ahmedabad for the degree D.M. (Medical Oncology)
• Presented paper (Poster presentation) on patterns of relapse in acute leukemia at the Indian Society of Hematology and Blood Transfusion (ISHBT) conference held in February 1995 at Indore
• Co-authored a review article - 'Chemotherapy in Gastrointestinal Malignancies' -, which was accepted and published in Indian Journal of Medical & Pediatric Oncology
• Co-authored a paper - 'Comparative study of CHOP v/s CNOP in high grade NHL' - published in Indian Journal of ISHBT conference held at Indore (Feb 1995)
• Review article on the drug 2 - deoxycoformycin that was published in Indian Journal of Medical and Pediatric Oncology
• Presented a paper - 'Hepatitis B in Hematological Malignancies held at the ISHBT conference held at Bombay in January 1993
• Presented a paper (oral presentation) - 'Chronic, daily, oral administration of Etoposide in advanced, refractory malignancies' at the VIIth Biennial International Conference of Indian Society of Oncology, held at Lucknow in March 1996
• ORAL PAPER PRESENTATION - 'Chronic, daily, oral administration of Etoposide in advanced, refractory malignancies' - at the 3rd International Conference of ASIAN CLINICAL ONCOLOGY SOCIETY (ACOS) held in Kunming, CHINA between 15th - 17th August, 1996
• Presented two oral papers at the IXth biennial conference of Indian Society of Medical & Pediatric Oncology, held at Madurai, India between 14-16th February, 1997

             The two papers are as under:

                     i) Non-Candida albicans fungemia in neutropenic children: A report of 3 cases

                     ii) Tamoxifen induced endometrial pathology: A P.D. Hinduja National Hospital & Medical Research Centre experience

• Coauthor of the article “Motesanib or open-label bevacizumab, in combination with paclitaxel as first line treatment for HER-2- Negative locally recurrent or metastatic breast cancer: Phase 2, randomized, double-blind placebo-controlled study – The Lancet Oncology Volume 12 Issue 4, April II, Page 369-376